NPDT Evaluation in Children With CFTR and (PSC)
| Status: | Completed |
|---|---|
| Conditions: | Irritable Bowel Syndrome (IBS), Gastrointestinal, Gastrointestinal |
| Therapuetic Areas: | Gastroenterology |
| Healthy: | No |
| Age Range: | 12 - Any |
| Updated: | 12/15/2017 |
| Start Date: | January 2004 |
| End Date: | January 2006 |
Nasal Potential Difference Testing: Evaluation of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Function in Children With Primary Sclerosing Cholangitis (PSC)
The investigators hypothesize that PSC in children is associated with mutations and
functional changes of the cystic fibrosis (CF) gene.
functional changes of the cystic fibrosis (CF) gene.
The purpose of this protocol is to perform Nasal Transepithelial Potential Difference (NTPD)
testing to assess the function of the cystic fibrosis gene product, a chloride channel
referred to as CFTR, in patients diagnosed with PSC and/or inflammatory bowel disease in
childhood and currently 12 years of age and greater.
Dr. Freedman's laboratory has shown that there is an increased prevalence of CFTR
abnormalities in adults with PSC as demonstrated by genotype and phenotype analysis. We
hypothesize that abnormalities in CFTR based on exhaustive genotype and phenotype assessments
are associated with the presence of PSC in children. We would like to enroll patients with
inflammatory bowel disease and no PSC to use as a "control group".
Subjects with PSC and/or inflammatory bowel disease diagnosed in childhood, currently aged 12
years and above, will be enrolled in study protocols at Children's Hospital in Boston, which
will have received their local IRB approval. The only role for BIDMC will be to perform NTPD
testing on these subjects. No other assessment or testing will be performed at our site. We
will not be involved in any other aspect of care for these subjects.
testing to assess the function of the cystic fibrosis gene product, a chloride channel
referred to as CFTR, in patients diagnosed with PSC and/or inflammatory bowel disease in
childhood and currently 12 years of age and greater.
Dr. Freedman's laboratory has shown that there is an increased prevalence of CFTR
abnormalities in adults with PSC as demonstrated by genotype and phenotype analysis. We
hypothesize that abnormalities in CFTR based on exhaustive genotype and phenotype assessments
are associated with the presence of PSC in children. We would like to enroll patients with
inflammatory bowel disease and no PSC to use as a "control group".
Subjects with PSC and/or inflammatory bowel disease diagnosed in childhood, currently aged 12
years and above, will be enrolled in study protocols at Children's Hospital in Boston, which
will have received their local IRB approval. The only role for BIDMC will be to perform NTPD
testing on these subjects. No other assessment or testing will be performed at our site. We
will not be involved in any other aspect of care for these subjects.
Inclusion Criteria:
- 12 years of age and older
- Must have diagnosis of primary sclerosing cholangitis and/or inflammatory bowel
disease
- Absence of other liver disease, such as viral hepatitis, drug-induced liver disease,
and metabolic/hereditary liver disease
- No exclusion based on sex, race, and ethnic background
We found this trial at
1
site
Beth Israel Deaconess Medical Center Beth Israel Deaconess Medical Center (BIDMC) is one of the...
Click here to add this to my saved trials
